In Info on 2014/06/12 at 7:05 pm
The medical device we designed to help midwives monitor labour with minimum interruption has seen the light! Different newspapers and media have been attracted to our invention, a team effort from our colleagues in Univ of Edinburgh and NHS, Heriot-Watt University, and us in Loughborough.
This has been a great enterprising opportunity for us. Being able to form a team with engineers, designers, medics and business developers has been truly rewarding. We all showed great enthusiasm and reached out to understand each others’ ‘language’ so we could bring the project to a fruitful completion. Working with midwives for the development of a new medical device was great because they were able to provide us with insightful input during the design stages, and with useful feedback in the development phase. We hope the device will help the midwives carry out their work in more comfortable conditions, and for future mothers-to-be to benefit from this device that allows them to experience a more dignifying labour.
The work has been presented at the Perinatal Medicine 2014 (Harrogate International Centre, Monday 9th – Wednesday 11th June 2014).
The press releases can be found here and here
More press material can be found here and here and here.
In Publications on 2014/03/06 at 12:12 am
The work done by my colleague Dr Asier Unciti-Broceta and our ‘dream team’ has been published in Nature Communications.
Asier proudly presents to the world the work done using his clever “bioorthogonal” method for activating a prodrug by palladium catalyzed dealkylation. What motivates us is to move towards the eradication of the side effects of chemotheraphy (e.g. depleted immune system, hair loss, tiredness, etc) in the very near future. This is done by focusing the cancer treatment only to the affected area. Like a ‘trojan horse’, in our vision we implant the engineered catalyst carrier first. Then, by a selective activation via oral drugs, we produce the chemo-destructive effect with maximum effect on the targeted area, and minimal negative effects (i.e. death) on healthy tissue.
The technology in a ‘nutshell’
The full paper can be found here.
The press release by University of Edinburgh can be viewed here.
Asier is an academic fellow at the Edinburgh Cancer Research UK Centre at the MRC Institute of Genetics and Molecular Medicine, the University of Edinburgh.